- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00978432
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2 Study to Evaluate the Efficacy of Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a prospective, non-randomized, un-blinded phase 2 efficacy trial using a mechanistic target of rapamycin (mTOR) inhibitor and a histone deacetylase (HDAC) inhibitor for epigenetic targeted therapies.
Subjects will receive RAD001 and LBH589 given in two to thirteen, 28-day cycles. Subjects will be assessed for disease status after 2 cycles and then after every 4 cycles. Subjects with progressive disease will stop after 2 cycles. Subjects with stable disease or better les may receive up to 13 cycles. LBH589 was given at 40mg when the study first opened and was changed to 20mg po shortly thereafter. LBH589 is taken on days M/W/F. RAD001 was given at 10mg po daily for Part 1. In Part 2, LBH589 is given at 15mg and RAD001 is given at 7.5mg.
Treatment will be administered on an outpatient basis. Patients will be followed for up to 2 years after completion of therapy or until progression of disease or death.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
de novo or transformed Diffuse large B cell non-Hodgkin lymphoma (DLBCL). DLBCL-like lymphomas allowed:
- Epstei-Barr virus (EBV)+ DLBCL in elderly,
- DLBCL with chronic inflammation,
- Primary cutaneous DLBCL, leg type,
- B cell lymphoma unclassifiable - between DLBCL and Burkitt lymphoma,
- B cell lymphoma unclassifiable - between large B cell lymphoma and classical Hodgkin lymphoma,
- Anaplastic lymphoma kinase (ALK)+ large B cell lymphoma,
- T cell histiocyte rich large B cell lymphoma
- Primary mediastinal B cell lymphoma
- Follicular grade 3 B cell lymphoma
- Refractory or relapsed disease to >/= 1 prior treatment regimen: should include autologous stem cell transplant unless patient refused or ineligible.
- Age > 18 years old
- Eastern Cooperative Oncology Group (ECOG) performance status <2.
- Measurable or evaluable disease by physical exam, radiographs or bone marrow involvement
- Frozen tumor or paraffin-embedded sample available.
- 3-4 core fresh/fresh-frozen biopsy specimens available. Leukapheresis may be done for patients with leukocytosis.
- Laboratory Values per protocol.
Exclusion Criteria:
Laboratory Values
- Grade 3 hyperlipidemia (Serum cholesterol >400mg/dl or serum triglycerides >5 x ULN)
- Serum Glucose > 250mg/dl on >/= 2 checks on 2 separate days
- Diabetics accepted if sugars controlled
Unlimited prior chemotherapy regimens, however:
No prior exposure to RAD001 or LBH589 or drugs that target mTOR (sirolimus, temsirolimus, etc) or HDAC (vorinostat)
- No valproic acid during study or 5 days preceding start of first drug
- No chemotherapy, biologics or immunotherapy < 2 weeks before registration (6 weeks if last received bis-chloroethylnitrosourea (BCNU) or mitomycin C). Subjects must be recovered from therapy-related non-hematological toxicities to < grade 1 or baseline if started with > grade 1 toxicity.
- No time limit for radiation prior to registration.
- No radioimmunotherapy < 2 months prior to registration. Subjects must be recovered from therapy-related toxicities to < grade 1 or baseline if started with > grade 1 toxicity.
- No prior allogeneic stem cell transplantation unless allogeneic engraftment is <2%.
Subjects receiving chronic, systemic treatment with corticosteroids = to >20mg of prednisone per day.
- Subjects receiving replacement for adrenal insufficiency allowed.
- Topical or inhaled corticosteroids allowed.
- History of other primary malignancy < 3 years ago, except inactive basal, squamous cell carcinoma of the skin or superficial melanoma only requiring excision, prostate cancer with a prostate specific antigen (PSA) stable for >/=3 months, carcinoma in situ of cervix.
- Major surgery < 4 weeks before or Minor surgery < 2 weeks before registration. Subjects must be recovered from toxicities to < grade 1 or baseline if started with > grade 1 toxicity.
- Investigational drugs < 4 weeks prior to registration.
- Impaired Cardiac Function per protocol.
- Pregnant or breastfeeding females or adults of reproductive potential not using effective birth control
- Diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO) < 40% if tested (per protocol).
- Impaired lung function: O2 saturation 88% or less at rest on room air by Pulse Oximetry.
- Immunization with live attenuated vaccines < 1 week of study entry
- Impaired GI function or GI disease that may alter absorption of RAD001 or LBH589
- Concurrent severe &/or uncontrolled medical conditions
- Medications with risk of prolonging QT interval or inducing torsade de pointes or interacting with LBH589 and RAD001 may be used per the protocol.
- Active bleeding tendency
- Positive for HIV.
- Positive for Hepatitis C virus (HCV).
- History of non-compliance to medical regimens.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm 1a (RAD001 followed by LBH589)
Part 1a: Sequential single agent therapy with RAD001 and LBH589. Each agent will be given for four-six 28-day cycles. Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period. Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease. There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest. |
10 mg/day for Part 1 of the trial
Other Names:
40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
Other Names:
|
EXPERIMENTAL: Arm 1b (LBH589 followed by RAD001)
Part 1b: Sequential single agent therapy with LBH589 and RAD001 . Each agent will be given for four-six 28-day cycles. Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period. Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease. There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest. |
10 mg/day for Part 1 of the trial
Other Names:
40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
Other Names:
|
EXPERIMENTAL: Doublet (Combination RAD001 and LBH589)
Subjects will receive the doublet of RAD001 and LBH589 given in two to thirteen, 28-day cycles.
Subjects will be evaluated for the disease status after completion of cycle two and then after every 4 cycles.
Subjects with progressive disease will stop after 2 cycles.
Subjects with stable disease or better may receive up to 13 cycles.
LBH589 will start at 15mg po three days a week at least 2 days apart such as on days M/W/F or T/Th/Sat and RAD001 will start at 7.5mg po daily.
|
RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: after 2 cycles of each study drug or after 2 cycles of doublet, up to 24 weeks
|
Overall Response Rate is the number of participants with a partial and complete response assessed by the Updated Cheson criteria for lymphoma.
A complete response is complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy and normalization of those biochemical abnormalities.
If a subject has residual lesions on CT scan and the disease was fluorodeoxyglucose (FDG) avid pre-treatment, then that subject will be considered to be in a complete response.
Partial response is a greater than or equal to 50% decrease in the sum of the products of the greatest diameters of 6 largest dominant nodes or nodal masses.
No increase in size of nodes, liver or spleen and no new sites of disease
|
after 2 cycles of each study drug or after 2 cycles of doublet, up to 24 weeks
|
Assessment of Association Between Observed Response to RAD001 and LBH589 and the Response Predicted by Molecular Signatures Developed in Our Pre-clinical Model
Time Frame: From the start of combination therapy until a maximum of 2 years after completion of therapy
|
We will estimate the association of the molecular signature-predicted response to the doublet (CR+PR) with the observed response.
All evaluable patients will be used in estimating response.
The chi-square test with one-sided alpha of 0.10 will be used to test for the association between predicted and observed responses.
Contingency tables will be used to present these associations.
|
From the start of combination therapy until a maximum of 2 years after completion of therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Summary of Adverse Events (AEs)
Time Frame: From the time of first dose of study drug until 4 weeks after participant has stopped study drug; up to 1 year
|
Counts of adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose) experienced by patients on study drug(s).
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) is used to assess severity.
Relatedness to study drug is assessed by the investigator.
|
From the time of first dose of study drug until 4 weeks after participant has stopped study drug; up to 1 year
|
Distribution of Change Across Time of mTOR and HDAC-I Inhibition From Baseline Until After the 1st 2 Cycles of Study Drug in Patients Who Received LBH and RAD.
Time Frame: after 2 cycles of study therapy; up to 8 weeks
|
Serum markers will be measured on the first day of cycle 1 and on the first day of cycle 3.
The distribution of change across time in a marker will be summarized.
|
after 2 cycles of study therapy; up to 8 weeks
|
Evaluate the Association of Observed Response to the Doublet With the Response Predicted by Molecular Signatures for Activated B Cell Like (ABC) DLBCL and for Germinal Center B Cell Like (GCB) DLBCL.
Time Frame: up to 13 cycles of therapy; approximately 1 year
|
Response rates seen in subjects with activated B cell like DLBCL and for Germinal center B cell like DLBCL will be reported and assessed to see if GCB is associated with improved outcomes compared to ABC in subjects with relapsed disease who have received RAD + LBH. We will estimate the association of the ABC and GCB with the observed response. All evaluable patients will be used in estimating response. The chi-square test with one-sided alpha of 0.10 will be used to test for the association between predicted and observed responses. The number of responses to treatment were so few that we did not think we could get enough meaningful data for analysis. |
up to 13 cycles of therapy; approximately 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anne W. Beaven, MD, Duke University
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Histone Deacetylase Inhibitors
- Everolimus
- Panobinostat
Other Study ID Numbers
- Pro00012947
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Large B-cell Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on RAD001
-
Children's Hospital Medical Center, CincinnatiNovartisCompletedTuberous Sclerosis | AngiolipomaUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Renal Cell Carcinoma (mRCC)Germany
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Children's Hospital of Philadelphia; Washington... and other collaboratorsCompleted
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedLymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedBrain and Central Nervous System TumorsUnited States, Israel, Canada
-
University of ChicagoNovartis PharmaceuticalsTerminatedNon-Small Cell Lung CancerUnited States
-
Guangdong Provincial People's HospitalNovartisUnknownNeuroendocrine Tumors | Carcinoid TumorChina
-
Fox Chase Cancer CenterRecruitingMetastatic Pancreatic CancerUnited States
-
Novartis PharmaceuticalsTerminatedHepatocellular CarcinomaUnited States, Spain, Korea, Republic of, Netherlands, Taiwan